<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Lambert-Eaton myasthenic syndrome: Treatment and prognosis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Lambert-Eaton myasthenic syndrome: Treatment and prognosis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Lambert-Eaton myasthenic syndrome: Treatment and prognosis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            David H Weinberg, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jeremy M Shefner, MD, PhD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Patrick Y Wen, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Richard P Goddeau, Jr, DO, FAHA
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Oct 11, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Lambert-Eaton myasthenic syndrome (LEMS) is an uncommon disorder of neuromuscular junction transmission with the primary clinical manifestation of muscle weakness. Knowledge of subtle clinical features and laboratory abnormalities that accompany LEMS permits the early identification of the disorder. Early recognition of LEMS is particularly important because of its strong association with small cell lung cancer (SCLC). Although LEMS can occur at any point in the course of SCLC, it may serve as a marker for early disease and thus allow more effective treatment of this malignancy.
        </p>
        <p>
         This topic will review treatment for LEMS. The clinical features and diagnosis of this disorder are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5174.html" rel="external">
          "Lambert-Eaton myasthenic syndrome: Clinical features and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3052249120">
         <span class="h1">
          EVALUATION FOR MALIGNANCY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The first priority in the management of LEMS is to evaluate for a primary underlying malignancy. Treatment of the underlying malignancy may be the only intervention necessary to produce improvement in neurologic symptoms.
        </p>
        <p class="headingAnchor" id="H3053321936">
         <span class="h2">
          Small cell lung cancer
         </span>
         <span class="headingEndMark">
          —
         </span>
         Small cell lung cancer (SCLC) is the most common associated tumor in patients with LEMS. Suspicion for lung cancer is particularly high among patients with a history of smoking who are ≥50 years of age [
         <a href="#rid1">
          1
         </a>
         ]. Population studies have consistently shown that approximately one-half of LEMS cases are associated with a malignancy, which is usually SCLC. In a clinical series that included 50 patients with LEMS, SCLC was present in 21 of 25 patients (84 percent) with cancer [
         <a href="#rid2">
          2
         </a>
         ]. From the perspective of patients who have SCLC, the incidence and prevalence of LEMS are estimated to be approximately 3 percent each [
         <a href="#rid3">
          3-5
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4628.html" rel="external">
          "Pathobiology and staging of small cell carcinoma of the lung"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H719320846">
         <span class="h2">
          Other malignancies
         </span>
         <span class="headingEndMark">
          —
         </span>
         The other malignancies most convincingly associated with LEMS are lymphoproliferative disorders, including Hodgkin lymphoma [
         <a href="#rid6">
          6-8
         </a>
         ]. LEMS has been rarely associated with atypical carcinoid [
         <a href="#rid9">
          9
         </a>
         ], Merkel cell carcinoma [
         <a href="#rid10">
          10
         </a>
         ], thymic neuroendocrine carcinoma [
         <a href="#rid11">
          11
         </a>
         ], malignant thymoma [
         <a href="#rid12">
          12
         </a>
         ], thymic small cell carcinoma [
         <a href="#rid13">
          13
         </a>
         ], and neuroblastoma [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1022128772">
         <span class="h2">
          Initial evaluation
         </span>
         <span class="headingEndMark">
          —
         </span>
         For all patients with newly diagnosed LEMS and no known cancer, we recommend initial malignancy evaluation with computed tomography (CT) of the chest, abdomen, and pelvis. Magnetic resonance imaging (MRI) of the brain and/or spinal cord should also be obtained if there are focal neurologic symptoms or signs suggesting involvement of the central nervous system (CNS).
        </p>
        <p>
         Some experts suggest performing 18-F fluorodeoxyglucose positron emission tomography (FDG-PET) as part of the initial screening for malignancy if the CT scans are nondiagnostic [
         <a href="#rid14">
          14
         </a>
         ]. We recommend FDG-PET imaging for all high-risk patients, such as those with a Dutch-English LEMS Tumor Association Prediction (DELTA-P) score ≥3 (
         <a class="graphic graphic_table graphicRef106996" href="/z/d/graphic/106996.html" rel="external">
          table 1
         </a>
         ), who have negative CT imaging. The DELTA-P score is described below. (See
         <a class="local">
          'DELTA-P score'
         </a>
         below.)
        </p>
        <p>
         We also suggest testing for SOX antibodies (see
         <a class="local">
          'SOX and other antineuronal antibodies'
         </a>
         below) for any patient with suspected LEMS without a known SCLC and suggest FDG-PET imaging for patients of any age or smoking history who have elevated SOX antibodies and nondiagnostic CT imaging.
        </p>
        <p>
         A general overview of the initial evaluation, diagnosis, and staging of patients with suspected lung cancer is provided elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/4632.html" rel="external">
          "Overview of the initial evaluation, diagnosis, and staging of patients with suspected lung cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4175126715">
         <span class="h2">
          Follow up surveillance when initial evaluation is negative
         </span>
         <span class="headingEndMark">
          —
         </span>
         If the initial malignancy evaluation is negative in patients with LEMS, we recommend repeating the chest CT scan at three months for high-risk patients (eg, a DELTA-P score ≥3) and patients with elevated SOX antibody titers and at six months for low-risk patients. This is followed by screening at least
         <strong>
          <em>
          </em>
         </strong>
         every six months up until at least
         <em>
         </em>
         two years if testing remains unrevealing [
         <a href="#rid15">
          15
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5188.html" rel="external">
          "Overview of paraneoplastic syndromes of the nervous system", section on 'Search for occult malignancy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3729397249">
         <span class="h2">
          DELTA-P score
         </span>
         <span class="headingEndMark">
          —
         </span>
         The Dutch-English LEMS Tumor Association Prediction (DELTA-P) score (
         <a class="graphic graphic_table graphicRef106996" href="/z/d/graphic/106996.html" rel="external">
          table 1
         </a>
         ) may be useful to identify patients at low and high risk for SCLC and thereby guide the extent of testing for SCLC. In a cohort study of Dutch and English patients with LEMS, clinical factors within the first three months from LEMS onset that independently predicted the presence of SCLC were age ≥50 years, history of smoking at diagnosis, weight loss ≥5 percent, bulbar involvement, erectile dysfunction in men, and Karnofsky Performance Status (
         <a class="graphic graphic_table graphicRef58785" href="/z/d/graphic/58785.html" rel="external">
          table 2
         </a>
         ) score &lt;70 [
         <a href="#rid16">
          16
         </a>
         ]. Using these factors, the investigators derived the DELTA-P score (
         <a class="graphic graphic_table graphicRef106996" href="/z/d/graphic/106996.html" rel="external">
          table 1
         </a>
         ). A DELTA-P score of 0 or 1 was associated with an SCLC probability of 0 and 3 percent, respectively. DELTA-P scores of 4, 5, and 6 were associated with an SCLC probability of 94, 97, and 100 percent, respectively.
        </p>
        <p class="headingAnchor" id="H3761545508">
         <span class="h2">
          SOX and other antineuronal antibodies
         </span>
         <span class="headingEndMark">
          —
         </span>
         SOX (SRY-related high mobility group [HMG] box) antibodies are common in SCLC. In one report, SOX antibodies were detected in 29 of 43 patients (67 percent) with LEMS associated with SCLC and only 2 of 43 patients (5 percent) with nontumor LEMS [
         <a href="#rid17">
          17
         </a>
         ]. Additionally, the presence of GABAb and N-type voltage-gated calcium channel antibodies predict a significantly higher risk of tumor-associated LEMS. The presence of antineuronal antibodies can also improve the detection of cancer in LEMS patients with low DELTA-P scores of 1 to 2 [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3761242139">
         <span class="h1">
          INITIAL SYMPTOMATIC THERAPY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several medications increase the amount of acetylcholine available at the postsynaptic membrane. The most effective agents increase the presynaptic release of acetylcholine and thereby reverse the underlying physiologic deficit present in LEMS. If adequate to induce stable functional muscle strength, no further treatment may be needed.
        </p>
        <p class="headingAnchor" id="H1273903380">
         <span class="h2">
          Mild weakness, no functional impact
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with LEMS who have mild weakness that does not interfere with function can be monitored without the use of symptomatic or immunologic therapy (
         <a class="graphic graphic_algorithm graphicRef54686" href="/z/d/graphic/54686.html" rel="external">
          algorithm 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H1280144944">
         <span class="h2">
          Moderate to severe weakness
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with moderate or severe weakness that does interfere with function, we suggest initiating
         <a class="drug drug_general" data-topicid="119856" href="/z/d/drug information/119856.html" rel="external">
          amifampridine
         </a>
         . If amifampridine is not tolerated or is unavailable,
         <a class="drug drug_general" data-topicid="9838" href="/z/d/drug information/9838.html" rel="external">
          pyridostigmine
         </a>
         could be considered.
        </p>
        <p class="headingAnchor" id="H1628431462">
         <span class="h3">
          Amifampridine (3,4-diaminopyridine)
         </span>
         <span class="headingEndMark">
          —
         </span>
         The aminopyridines are beneficial in patients with LEMS. The mechanism of action is potassium channel blockade that significantly prolongs the presynaptic nerve terminal membrane depolarization, which enhances calcium entry and thereby improves the release of acetylcholine.
        </p>
        <p>
         3,4-diaminopyridine (3,4-DAP) is the best-tolerated aminopyridine due to its limited central nervous system (CNS) penetration.
         <a class="drug drug_general" data-topicid="9095" href="/z/d/drug information/9095.html" rel="external">
          Dalfampridine
         </a>
         (4-aminopyridine) was the first aminopyridine to be recognized as having beneficial effects in LEMS. However, clinical use was limited by frequent toxicity in the therapeutic range (including generalized seizures), which required much higher doses than those now used in patients with multiple sclerosis, for example [
         <a href="#rid19">
          19
         </a>
         ]. 3,4-DAP has the same mechanism of action and considerably less CNS penetration than dalfampridine, making it the clear preference in LEMS.
        </p>
        <p>
         3,4-DAP was initially studied and developed as a base (3,4-DAP base), which was available in the United States through a compassionate use program from compounding pharmacies, and later formulated as an oral tablet.
         <a class="drug drug_general" data-topicid="119856" href="/z/d/drug information/119856.html" rel="external">
          Amifampridine
         </a>
         phosphate (Firdapse) was approved by the US Food and Drug Administration (FDA) in 2018 for use in adults and in 2022 for children age 6 years and older [
         <a href="#rid20">
          20,21
         </a>
         ].
        </p>
        <p>
         The effectiveness of 3,4-DAP compared with placebo for improving motor and autonomic symptoms in LEMS has been demonstrated in multiple small randomized controlled trials [
         <a href="#rid22">
          22-28
         </a>
         ]. In these trials, 3,4-DAP improved muscle strength in patients with LEMS, making it the most effective symptomatic treatment for LEMS [
         <a href="#rid26">
          26
         </a>
         ]. In the largest individual trial, 38 patients (≥18 years of age) with LEMS completed an open-label run-in phase of
         <a class="drug drug_general" data-topicid="119856" href="/z/d/drug information/119856.html" rel="external">
          amifampridine
         </a>
         and were then entered into a blinded two-week discontinuation phase in which they were randomly assigned to continued amifampridine or placebo (which included a seven-day taper off active drug) [
         <a href="#rid27">
          27
         </a>
         ]. By day 14, the patients in the amifampridine group had superior quantitative myasthenia gravis (QMG) scores (mean difference 1.7 points, 95% CI 0.0-3.4) and were less likely to experience clinically significant disease progression (6 versus 59 percent at day 8 and 12.5 versus 38 percent at 14 days). There were no statistically significant differences in timed walk testing or compound muscle action potential (CMAP) amplitudes.
        </p>
        <p>
         The recommended starting dose of
         <a class="drug drug_general" data-topicid="119856" href="/z/d/drug information/119856.html" rel="external">
          amifampridine
         </a>
         for adults and children weighing 45 kg or more is 15 to 30 mg daily taken orally in three to four divided doses [
         <a href="#rid21">
          21,29
         </a>
         ]. The dose can be titrated upwards based on effect and tolerability by 5 mg daily every three to four days. The maximum single dose is 20 mg and the maximum approved daily dose is 80 mg. However, 3,4-DAP base doses up to 100 mg/day have been widely used [
         <a href="#rid24">
          24
         </a>
         ]. For children less than 45 kg, the recommended starting dose is 5 to 15 mg divided three to four times daily with increases as needed in 2.5 to 5 mg increments every three to four days with a maximal daily dose of 10 mg per dose or 40 mg daily. The recommended starting dose of amifampridine for patients with kidney or liver impairment is the lowest recommended initial dose based on body weight and age category.
        </p>
        <p>
         The side effects of 3,4-DAP at typical therapeutic doses are usually mild, mainly perioral and extremity paresthesias in 50 to 60 percent of patients [
         <a href="#rid27">
          27
         </a>
         ]. Headache, nausea, abdominal pain, diarrhea, and elevated liver enzymes can also occur. 3,4-DAP has been associated with seizures, particularly at high doses [
         <a href="#rid30">
          30
         </a>
         ], and the FDA label for
         <a class="drug drug_general" data-topicid="119856" href="/z/d/drug information/119856.html" rel="external">
          amifampridine
         </a>
         includes a contraindication in patients with a history of seizure. A history of seizure has been an eligibility exclusion in most trials, and therefore experience is limited in patients with epilepsy. If the balance of risks and benefits is felt to favor use in a patient with symptomatic LEMS and epilepsy, 3,4-DAP should be used cautiously at the lowest dose possible. 3,4-DAP should also be used with caution in patients with severe asthma [
         <a href="#rid24">
          24,30
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2323302804">
         <span class="h3">
          Pyridostigmine if 3,4-DAP is not available
         </span>
         <span class="headingEndMark">
          —
         </span>
         The acetylcholinesterase inhibitors are, unfortunately, only marginally effective in isolation for the treatment of LEMS and should only be tried in patients who are intolerant of or do not have access to 3,4-DAP. Acetylcholinesterase inhibitors reduce the metabolism of acetylcholine, thereby increasing the amount available for acetylcholine receptor binding.
         <a class="drug drug_general" data-topicid="9838" href="/z/d/drug information/9838.html" rel="external">
          Pyridostigmine
         </a>
         is the best tolerated of the acetylcholinesterase inhibitors.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9838" href="/z/d/drug information/9838.html" rel="external">
          Pyridostigmine
         </a>
         has been used as adjunct treatment in patients receiving 3,4-DAP in the hope that this combination, which is well tolerated, confers additional symptomatic benefit. However, the utility of this approach is uncertain and high-quality data are sparse. One randomized controlled crossover trial of nine patients with LEMS compared 3,4-DAP, pyridostigmine, the combination of both drugs, and placebo [
         <a href="#rid22">
          22
         </a>
         ]. There was no benefit for pyridostigmine, either alone or in combination with 3,4-DAP, for the outcomes of muscle strength and CMAP amplitude.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9838" href="/z/d/drug information/9838.html" rel="external">
          Pyridostigmine
         </a>
         is used in a wide dose range between 30 and 180 mg at dosing intervals between three and six hours, depending upon side effects and clinical response. Nausea, abdominal cramping, and diarrhea are adverse effects seen in approximately 5 to 10 percent of patients and can be major limiting factors, but they are dose dependent, being uncommon at low doses and common at high doses. Acetylcholinesterase inhibitors have no major systemic toxicities.
        </p>
        <p class="headingAnchor" id="H1116256812">
         <span class="h1">
          IMMUNOTHERAPY FOR REFRACTORY WEAKNESS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The presence of LEMS is synonymous with the presence of antibodies directed against voltage-gated calcium channels (see
         <a class="medical medical_review" href="/z/d/html/5174.html" rel="external">
          "Lambert-Eaton myasthenic syndrome: Clinical features and diagnosis", section on 'Pathophysiology'
         </a>
         ). In patients with significant weakness and a limited response to the symptomatic therapies outlined above, a reduction in this aberrant immune response is often central to successful treatment. Several different strategies have been employed, including a variety of oral agents and immunomodifying treatments.
        </p>
        <p class="headingAnchor" id="H2211217905">
         <span class="h2">
          Our approach to refractory weakness
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with LEMS without malignancy or with a treated malignancy who have moderate or severe weakness that interferes with function and does not improve sufficiently with symptomatic therapy, we start immunomodulatory treatment.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For most patients with refractory LEMS, we suggest initial immunomodulatory treatment with intravenous immunoglobulin (
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         ) (
         <a class="graphic graphic_algorithm graphicRef54686" href="/z/d/graphic/54686.html" rel="external">
          algorithm 1
         </a>
         ). A typical course of IVIG is 2 g/kg total given over two to five days. (See
         <a class="local">
          'Intravenous immune globulin'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients who do not respond to or tolerate
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         , we use alternative immunomodulatory options.
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          Prednisone
         </a>
         may be as effective as IVIG, has the widest experience, and is cost-effective, but also has the greatest breadth of side effects.
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          Azathioprine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         mofetil, and
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         are less toxic than prednisone for long-term use but may not be as effective.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Our preferred alternative regimen to
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         is to start
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         (1 mg/kg per day, or 1 to 1.5 mg/kg every other day) and
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         (2 to 3 mg/kg per day) simultaneously, followed later by an attempt to taper or discontinue prednisone in order to reduce long-term prednisone toxicity. Unfortunately, this strategy may not be as successful in patients with LEMS as it is in patients with myasthenia gravis (MG) [
         <a href="#rid31">
          31
         </a>
         ]. Some experts are reluctant to use oral immunosuppressive agents such as azathioprine in patients with cancer because of concerns that such treatment may exacerbate the malignancy. (See
         <a class="local">
          'Prednisone'
         </a>
         below and
         <a class="local">
          'Other oral immunosuppressive agents'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Other reasonable choices include oral
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         (1 mg/kg per day, or 1 to 1.5 mg/kg every other day) alone,
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         alone at 2 to 3 mg/kg per day, other oral immunosuppressives (
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         and
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         ), or plasma exchange given as five or more exchanges (3 to 5 L of plasma each) over 7 to 14 days.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Plasma exchange is more cumbersome than
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         and is suggested for special circumstances such as IVIG intolerance or refractory disease in patients with a severe clinical course. (See
         <a class="local">
          'Plasma exchange'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          Rituximab
         </a>
         can also be used for patients with disease that is refractory to the other agents listed above.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h3">
          Intravenous immune globulin
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         therapy, a nonspecific immunomodulating therapy, has proven useful in a number of antibody-mediated diseases such as MG. A number of small studies conducted in the mid-1990s suggested benefit in LEMS as well, with both clinical improvement and a reduction in the voltage-gated calcium channel antibodies [
         <a href="#rid26">
          26,32-37
         </a>
         ]. A course of IVIG (total dose of 2 g/kg over two to five days) is often effective, and maintenance therapy with repeat infusions at 4- to 12-week intervals is a reasonable strategy for patients with symptom recurrence who responded to initial IVIG treatment.
        </p>
        <p>
         The only randomized trial of this therapy for LEMS involved nine patients who were treated in a crossover design with
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         (1 g/kg per day for two days) or placebo [
         <a href="#rid32">
          32
         </a>
         ]. There was significant improvement in serial measurements of limb, respiratory, and bulbar muscle strength associated with IVIG treatment, and a nonsignificant improvement in the resting compound muscle action potential (CMAP) amplitude.
        </p>
        <p>
         The benefits of
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         treatment seem to peak at approximately two to four weeks following the infusion (the half-life is roughly one month), followed by recurrent weakness over the subsequent weeks [
         <a href="#rid32">
          32-36
         </a>
         ]. The use of maintenance IVIG for recurrent weakness has been both feasible and beneficial [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p>
         Overall,
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         is well tolerated, but particular problems as well as several idiosyncratic reactions can be induced by the large volume of fluid required and by the increase in serum viscosity that occurs [
         <a href="#rid38">
          38
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4431.html" rel="external">
          "Overview of intravenous immune globulin (IVIG) therapy"
         </a>
         .)
        </p>
        <p>
         Numerous
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         products are available with different relative toxicities based upon the formulation. Thus, a good working familiarity with these preparations is recommended, particularly when ordering treatment for patients who may be at higher risk of complications from IVIG. This category includes patients with renal insufficiency and a serum creatinine &gt;1.5 mg/dL (&gt;133 micromol/L), cerebrovascular disease, peripheral artery disease, cardiovascular disease, or advanced age.
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h3">
          Prednisone
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are no large-scale treatment trials to guide medication selection, but many smaller studies and case reports have commented upon the efficacy of
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         alone [
         <a href="#rid39">
          39
         </a>
         ] or combined with
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         or plasmapheresis [
         <a href="#rid40">
          40-43
         </a>
         ]. Oral prednisone for LEMS is typically started at a dose of 1 mg/kg per day or 1 to 1.5 mg/kg every other day [
         <a href="#rid39">
          39
         </a>
         ]. This dose is maintained until clinically significant improvement is evident, which may take several months. At that point, a slow tapering of the prednisone dose can begin. Glucocorticoid tapering should be individualized in patients with LEMS, based upon the clinical situation. A reasonable tapering regimen with either a daily or alternate-day glucocorticoid treatment program is to decrease the dose every two weeks by 10 mg/day until the dose is ≤20 mg/day, or ≤30 mg every other day, at which point the dose reduction is slowed to 5 mg/day every two weeks. With doses ≤7.5 mg/day, tapering is often further slowed to 2 to 2.5 mg/day every two weeks.
        </p>
        <p>
         Attention to symptoms suggestive of adrenal insufficiency is important for patients who have been exposed to daily glucocorticoids for longer than three weeks, particularly those taking the dose equivalent of
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         ≥10 mg/day. However, adrenal testing is seldom needed.
        </p>
        <p>
         The risk of hypothalamic-pituitary-adrenal axis suppression and adrenal insufficiency due to glucocorticoid therapy and tapering is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/124.html" rel="external">
          "Pharmacologic use of glucocorticoids"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/159.html" rel="external">
          "Clinical manifestations of adrenal insufficiency in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1861930555">
         <span class="h3">
          Other oral immunosuppressive agents
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          Azathioprine
         </a>
         can be added as a glucocorticoid-sparing medication, typically starting at 50 mg twice a day, and increasing by 50 mg weekly up to a total dose of 2 to 3 mg/kg per day. Azathioprine is often given in divided doses to reduce gastrointestinal side effects, but it can be given as a single daily dose. The most common adverse effect with azathioprine is a reversible flu-like illness with fever, nausea, vomiting, and malaise. Less common serious adverse effects include infection, hepatotoxicity, and dose-related bone marrow suppression with leukopenia and/or thrombocytopenia. (See
         <a class="medical medical_review" href="/z/d/html/7994.html" rel="external">
          "Pharmacology and side effects of azathioprine when used in rheumatic diseases"
         </a>
         .)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          Mycophenolate
         </a>
         mofetil may be substituted in patients who do not tolerate
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         [
         <a href="#rid43">
          43
         </a>
         ]. The standard adult dose is 1000 mg twice a day on an empty stomach, but doses up to 1500 mg twice a day are occasionally used. Side effects are generally few with mycophenolate. The most common adverse side effects are gastrointestinal, mostly nausea or diarrhea. Leukopenia can also occur in some patients. All patients should have periodic surveillance laboratory monitoring including blood counts and trough mycophenolate levels for those taking higher doses.
        </p>
        <p>
         Although efficacy has not been well documented,
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         or the combination of
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         and an oral immunosuppressive agent would be reasonable in patients with LEMS that is refractory to the more established agents [
         <a href="#rid44">
          44
         </a>
         ]. Hypertension and nephrotoxicity are the most common limiting adverse effects of cyclosporine. Other adverse effects include tremor, nausea, gingival hyperplasia, myalgias and flu-like symptoms, and hypertrichosis. The risk of malignancy, primarily squamous cell skin cancer and lymphoma, may be increased with long-term use.
        </p>
        <p class="headingAnchor" id="H878355138">
         <span class="h3">
          Rituximab
         </span>
         <span class="headingEndMark">
          —
         </span>
         In retrospective case reports, treatment with intravenous
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         was associated with improvement in a few patients with LEMS who had previously been treated with multiple other immunosuppressive therapies [
         <a href="#rid45">
          45,46
         </a>
         ]. Rituximab is therefore reserved for patients with disease that is refractory to other immunosuppressive treatments.
        </p>
        <p class="headingAnchor" id="H98835328">
         <span class="h3">
          Plasma exchange
         </span>
         <span class="headingEndMark">
          —
         </span>
         Plasma exchange (plasmapheresis) is an attractive therapy for a putative antibody-mediated disorder, and benefit was noted in the early 1980s in several small case series [
         <a href="#rid40">
          40-42,47
         </a>
         ]. However, patients with LEMS do not respond as rapidly to plasma exchange as do those with MG. In addition, the benefit of plasma exchange is only short term, due to continued production of the offending antibodies, and repeated treatment is necessary. Nevertheless, combined therapy with plasma exchange and oral immunosuppressive agents remains a beneficial approach for some refractory patients [
         <a href="#rid41">
          41,47
         </a>
         ].
        </p>
        <p>
         There are inadequate data to determine the best plasma exchange treatment protocol for LEMS. Five exchanges (3 to 5 L of plasma each) over 7 to 14 days is the typical course of treatment for MG, and this represents a reasonable protocol for patients with LEMS, given the pathogenic similarities between the two disorders. On the other hand, anecdotal evidence suggests that more than five exchanges may be necessary to achieve maximum improvement [
         <a href="#rid42">
          42
         </a>
         ].
        </p>
        <p>
         The utility of plasma exchange is limited for many patients by several factors, including the need for vascular access, the limited availability of the procedure in many geographic areas, and the high cost of treatment.
        </p>
        <p class="headingAnchor" id="H3661787963">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The prognosis of LEMS differs between paraneoplastic and nonparaneoplastic LEMS.
        </p>
        <p class="headingAnchor" id="H2332397394">
         <span class="h2">
          Paraneoplastic LEMS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Survival is usually shortened in paraneoplastic LEMS due to progression of the underlying neoplasm, which is typically small cell lung cancer (SCLC). The most important prognostic factor in patients with SCLC is the extent of disease (stage) at presentation, as reviewed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/4639.html" rel="external">
          "Overview of the initial treatment and prognosis of lung cancer", section on 'SCLC'
         </a>
         .)
        </p>
        <p>
         There is good evidence that the presence of LEMS is associated with longer survival in patients with SCLC [
         <a href="#rid3">
          3,48-51
         </a>
         ]. As an example, one report found that the median survival was longer for 31 patients with SCLC and LEMS compared with 279 patients who had SCLC without neurologic illness (18 versus 9.5 months; hazard ratio 1.8, 95% CI 1.1-2.7) [
         <a href="#rid49">
          49
         </a>
         ]. The presence of LEMS was an independent predictor of prolonged survival. Among patients who have LEMS with malignancy, those with SCLC had a longer survival than patients with non-SCLC tumors (17 versus 7 months) [
         <a href="#rid51">
          51
         </a>
         ].
        </p>
        <p>
         With treatment of SCLC, limited evidence suggests that most patients with LEMS experience at least partial remission in the clinical symptoms of LEMS-related muscle weakness [
         <a href="#rid52">
          52-54
         </a>
         ] and the associated
         <strong>
          <em>
          </em>
         </strong>
         electrophysiologic abnormalities [
         <a href="#rid55">
          55
         </a>
         ]. However, weakness can persist after treatment of SCLC. (See
         <a class="medical medical_review" href="/z/d/html/4634.html" rel="external">
          "Limited-stage small cell lung cancer: Initial management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4633.html" rel="external">
          "Extensive-stage small cell lung cancer: Initial management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4614.html" rel="external">
          "Treatment of refractory and relapsed small cell lung cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2664420966">
         <span class="h2">
          Nonparaneoplastic LEMS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Limited data suggest that life expectancy in nonparaneoplastic LEMS is normal [
         <a href="#rid51">
          51
         </a>
         ] or nearly normal [
         <a href="#rid31">
          31
         </a>
         ]. However, a significant minority have physical limitations or are disabled. In a long-term study of 47 patients with LEMS who did not have SCLC, 10 patients died at a mean age of 70 years and after a median symptom duration of 11 years [
         <a href="#rid31">
          31
         </a>
         ]. Most of the deaths were unrelated to LEMS, although two were possibly related to complications of glucocorticoid therapy.
        </p>
        <p>
         Among 43 patients in the study treated with immunosuppression for over 1 year (median treatment duration 6 years; range 1.3 to 17 years), muscle strength scores were improved in 88 percent [
         <a href="#rid31">
          31
         </a>
         ]. However, among survivors at last follow-up, approximately 30 percent required a wheelchair for mobility either at all times or for moving outside the house.
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Evaluation for malignancy
         </strong>
         – The aggressive search for and treatment of a primary underlying malignancy in patients with any risk factors for small cell lung cancer (SCLC) is central to the management of patients with Lambert-Eaton myasthenic syndrome (LEMS). (See
         <a class="local">
          'Evaluation for malignancy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Initial symptomatic therapy with
         </strong>
         <a class="drug drug_general" data-topicid="119856" href="/z/d/drug information/119856.html" rel="external">
          amifampridine
         </a>
         <strong>
         </strong>
         – For patients with LEMS with or without a malignancy who have weakness that interferes with function (
         <a class="graphic graphic_algorithm graphicRef54686" href="/z/d/graphic/54686.html" rel="external">
          algorithm 1
         </a>
         ), we suggest initial symptomatic therapy with amifampridine (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). Amifampridine is the phosphate salt of 3,4-diaminopyridine (3,4-DAP) that is approved for use in some regions, including Europe and the United States; compounded 3,4-DAP base may be an option through compassionate use programs if amifampridine is unavailable. (See
         <a class="local">
          'Amifampridine (3,4-diaminopyridine)'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Immunotherapy for refractory weakness
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          IVIG
         </strong>
         – For patients with LEMS without malignancy or with a treated malignancy who have moderate or severe weakness that interferes with function and does not improve sufficiently with symptomatic therapy (
         <a class="graphic graphic_algorithm graphicRef54686" href="/z/d/graphic/54686.html" rel="external">
          algorithm 1
         </a>
         ), we suggest initial use of intravenous
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         (IVIG) at a dose of 2 g/kg total over two to five days, rather than oral immunosuppressive drugs or plasma exchange (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Intravenous immune globulin'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         For patients with symptom recurrence who respond to initial
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         treatment, we suggest maintenance therapy with repeat IVIG infusions at 4- to 12-week intervals determined by symptomatic need.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Alternative and adjunctive options
         </strong>
         – Our preferred alternative regimen to
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         is to simultaneously start oral
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         , 1 mg/kg per day or 1 to 1.5 mg/kg every other day, and
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         2 to 3 mg/kg per day, followed later by an attempt to taper or discontinue prednisone. (See
         <a class="local">
          'Our approach to refractory weakness'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Other reasonable choices would be oral
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         (1 mg/kg per day or 1 to 1.5 mg/kg every other day) alone,
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         alone at 2 to 3 mg/kg per day, other oral immunosuppressives (
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         and
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         ), or plasma exchange given as five or more exchanges (3 to 5 L of plasma each) over 7 to 14 days. (See
         <a class="local">
          'Prednisone'
         </a>
         above and
         <a class="local">
          'Other oral immunosuppressive agents'
         </a>
         above and
         <a class="local">
          'Plasma exchange'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prognosis
         </strong>
         – Survival is usually shortened in paraneoplastic LEMS due to progression of the underlying neoplasm, which is typically SCLC. The most important prognostic factor in patients with SCLC is the extent of disease (stage) at presentation. Limited data suggest that life expectancy in nonparaneoplastic LEMS is normal or nearly normal, but a significant minority are disabled. (See
         <a class="local">
          'Prognosis'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Sanders DB, Guptill JT. Myasthenia gravis and Lambert-Eaton myasthenic syndrome. Continuum (Minneap Minn) 2014; 20:1413.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Neill JH, Murray NM, Newsom-Davis J. The Lambert-Eaton myasthenic syndrome. A review of 50 cases. Brain 1988; 111 ( Pt 3):577.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wirtz PW, Lang B, Graus F, et al. P/Q-type calcium channel antibodies, Lambert-Eaton myasthenic syndrome and survival in small cell lung cancer. J Neuroimmunol 2005; 164:161.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elrington GM, Murray NM, Spiro SG, Newsom-Davis J. Neurological paraneoplastic syndromes in patients with small cell lung cancer. A prospective survey of 150 patients. J Neurol Neurosurg Psychiatry 1991; 54:764.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Payne M, Bradbury P, Lang B, et al. Prospective study into the incidence of Lambert Eaton myasthenic syndrome in small cell lung cancer. J Thorac Oncol 2010; 5:34.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Argov Z, Shapira Y, Averbuch-Heller L, Wirguin I. Lambert-Eaton myasthenic syndrome (LEMS) in association with lymphoproliferative disorders. Muscle Nerve 1995; 18:715.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lemal R, Chaleteix C, Minard P, et al. Large granular lymphocytic leukemia associated with Lambert-Eaton Myasthenic Syndrome: A case report. Leuk Res Rep 2013; 2:32.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hajjar M, Markowitz J, Darras BT, et al. Lambert-Eaton syndrome, an unrecognized treatable pediatric neuromuscular disorder: three patients and literature review. Pediatr Neurol 2014; 50:11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gutmann L, Phillips LH 2nd, Gutmann L. Trends in the association of Lambert-Eaton myasthenic syndrome with carcinoma. Neurology 1992; 42:848.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Siau RT, Morris A, Karoo RO. Surgery results in complete cure of Lambert-Eaton myasthenic syndrome in a patient with metastatic Merkel cell carcinoma. J Plast Reconstr Aesthet Surg 2014; 67:e162.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nalbantoglu M, Kose L, Uzun N, et al. Lambert-Eaton myasthenic syndrome associated with thymic neuroendocrine carcinoma. Muscle Nerve 2015; 51:936.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lauritzen M, Smith T, Fischer-Hansen B, et al. Eaton-Lambert syndrome and malignant thymoma. Neurology 1980; 30:634.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hashimoto S, Hayasaka K, Suzuki K, et al. Thymic Small Cell Carcinoma Associated With Lambert-Eaton Myasthenic Syndrome. Ann Thorac Surg 2020; 109:e347.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Titulaer MJ, Wirtz PW, Willems LN, et al. Screening for small-cell lung cancer: a follow-up study of patients with Lambert-Eaton myasthenic syndrome. J Clin Oncol 2008; 26:4276.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Titulaer MJ, Soffietti R, Dalmau J, et al. Screening for tumours in paraneoplastic syndromes: report of an EFNS task force. Eur J Neurol 2011; 18:19.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Titulaer MJ, Maddison P, Sont JK, et al. Clinical Dutch-English Lambert-Eaton Myasthenic syndrome (LEMS) tumor association prediction score accurately predicts small-cell lung cancer in the LEMS. J Clin Oncol 2011; 29:902.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Titulaer MJ, Klooster R, Potman M, et al. SOX antibodies in small-cell lung cancer and Lambert-Eaton myasthenic syndrome: frequency and relation with survival. J Clin Oncol 2009; 27:4260.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maddison P, Gozzard P, Sadalage G, et al. Neuronal antibody detection and improved lung cancer prediction in Lambert-Eaton myasthenic syndrome. J Neuroimmunol 2020; 340:577149.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murray NM, Newsom-Davis J. Treatment with oral 4-aminopyridine in disorders of neuromuscular transmission. Neurology 1981; 31:265.
          </a>
         </li>
         <li class="breakAll">
          https://ir.catalystpharma.com/news-releases/news-release-details/fda-approves-firdapser-amifampridine-treatment-lambert-eaton.
         </li>
         <li class="breakAll">
          FIRDAPSE® (amifampridine) tablets, for oral use. US Food and Drug Administration. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208078s008lbl.pdf (Accessed on November 03, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wirtz PW, Verschuuren JJ, van Dijk JG, et al. Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert-Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study. Clin Pharmacol Ther 2009; 86:44.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sanders DB, Massey JM, Sanders LL, Edwards LJ. A randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome. Neurology 2000; 54:603.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McEvoy KM, Windebank AJ, Daube JR, Low PA. 3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome. N Engl J Med 1989; 321:1567.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oh SJ, Claussen GG, Hatanaka Y, Morgan MB. 3,4-Diaminopyridine is more effective than placebo in a randomized, double-blind, cross-over drug study in LEMS. Muscle Nerve 2009; 40:795.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Keogh M, Sedehizadeh S, Maddison P. Treatment for Lambert-Eaton myasthenic syndrome. Cochrane Database Syst Rev 2011; :CD003279.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oh SJ, Shcherbakova N, Kostera-Pruszczyk A, et al. Amifampridine phosphate (Firdapse(®)) is effective and safe in a phase 3 clinical trial in LEMS. Muscle Nerve 2016; 53:717.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sanders DB, Juel VC, Harati Y, et al. 3,4-diaminopyridine base effectively treats the weakness of Lambert-Eaton myasthenia. Muscle Nerve 2018; 57:561.
          </a>
         </li>
         <li class="breakAll">
          https://www.firdapse.com/pdf/firdapse-pi.pdf.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wirtz PW, Titulaer MJ, Gerven JM, Verschuuren JJ. 3,4-diaminopyridine for the treatment of Lambert-Eaton myasthenic syndrome. Expert Rev Clin Immunol 2010; 6:867.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maddison P, Lang B, Mills K, Newsom-Davis J. Long term outcome in Lambert-Eaton myasthenic syndrome without lung cancer. J Neurol Neurosurg Psychiatry 2001; 70:212.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bain PG, Motomura M, Newsom-Davis J, et al. Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome. Neurology 1996; 47:678.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Muchnik S, Losavio AS, Vidal A, et al. Long-term follow-up of Lambert-Eaton syndrome treated with intravenous immunoglobulin. Muscle Nerve 1997; 20:674.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rich MM, Teener JW, Bird SJ. Treatment of Lambert-Eaton syndrome with intravenous immunoglobulin. Muscle Nerve 1997; 20:614.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Takano H, Tanaka M, Koike R, et al. Effect of intravenous immunoglobulin in Lambert-Eaton myasthenic syndrome with small-cell lung cancer: correlation with the titer of anti-voltage-gated calcium channel antibody. Muscle Nerve 1994; 17:1073.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bird SJ. Clinical and electrophysiologic improvement in Lambert-Eaton syndrome with intravenous immunoglobulin therapy. Neurology 1992; 42:1422.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patwa HS, Chaudhry V, Katzberg H, et al. Evidence-based guideline: intravenous immunoglobulin in the treatment of neuromuscular disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2012; 78:1009.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wittstock M, Benecke R, Zettl UK. Therapy with intravenous immunoglobulins: complications and side-effects. Eur Neurol 2003; 50:172.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Streib EW, Rothner AD. Eaton-Lambert myasthenic syndrome: long-term treatment of three patients with prednisone. Ann Neurol 1981; 10:448.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lang B, Newsom-Davis J, Wray D, et al. Autoimmune aetiology for myasthenic (Eaton-Lambert) syndrome. Lancet 1981; 2:224.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dau PC, Denys EH. Plasmapheresis and immunosuppressive drug therapy in the Eaton-Lambert syndrome. Ann Neurol 1982; 11:570.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Newsom-Davis J, Murray NM. Plasma exchange and immunosuppressive drug treatment in the Lambert-Eaton myasthenic syndrome. Neurology 1984; 34:480.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Newsom-Davis J. Therapy in myasthenia gravis and Lambert-Eaton myasthenic syndrome. Semin Neurol 2003; 23:191.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sanders DB. Lambert-eaton myasthenic syndrome: diagnosis and treatment. Ann N Y Acad Sci 2003; 998:500.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maddison P, McConville J, Farrugia ME, et al. The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 2011; 82:671.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boutin E, Rey C, Romeu M, et al. [Favourable outcome after treatment with rituximab in a case of seronegative non-paraneoplastic Lambert-Eaton myasthenic syndrome]. Rev Med Interne 2013; 34:493.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Motomura M, Hamasaki S, Nakane S, et al. Apheresis treatment in Lambert-Eaton myasthenic syndrome. Ther Apher 2000; 4:287.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maddison P, Newsom-Davis J, Mills KR, Souhami RL. Favourable prognosis in Lambert-Eaton myasthenic syndrome and small-cell lung carcinoma. Lancet 1999; 353:117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maddison P, Gozzard P, Grainge MJ, Lang B. Long-term survival in paraneoplastic Lambert-Eaton myasthenic syndrome. Neurology 2017; 88:1334.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Titulaer MJ, Verschuuren JJ. Lambert-Eaton myasthenic syndrome: tumor versus nontumor forms. Ann N Y Acad Sci 2008; 1132:129.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lipka AF, Boldingh MI, van Zwet EW, et al. Long-term follow-up, quality of life, and survival of patients with Lambert-Eaton myasthenic syndrome. Neurology 2020; 94:e511.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berglund S, Eriksson M, von Eyben FE, et al. Remission by chemotherapy of the Eaton-Lambert myasthenic syndrome in a patient with small cell bronchogenic carcinoma. Acta Med Scand 1982; 212:429.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jenkyn LR, Brooks PL, Forcier RJ, et al. Remission of the Lambert-Eaton syndrome and small cell anaplastic carcinoma of the lung induced by chemotherapy and radiotherapy. Cancer 1980; 46:1123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chalk CH, Murray NM, Newsom-Davis J, et al. Response of the Lambert-Eaton myasthenic syndrome to treatment of associated small-cell lung carcinoma. Neurology 1990; 40:1552.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oh SJ. SFEMG improvement with remission in the cancer-associated Lambert-Eaton myasthenic syndrome. Muscle Nerve 1989; 12:844.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 5134 Version 30.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25299290" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Myasthenia gravis and Lambert-Eaton myasthenic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2838124" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : The Lambert-Eaton myasthenic syndrome. A review of 50 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15904978" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : P/Q-type calcium channel antibodies, Lambert-Eaton myasthenic syndrome and survival in small cell lung cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1659614" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Neurological paraneoplastic syndromes in patients with small cell lung cancer. A prospective survey of 150 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19934775" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Prospective study into the incidence of Lambert Eaton myasthenic syndrome in small cell lung cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7783761" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Lambert-Eaton myasthenic syndrome (LEMS) in association with lymphoproliferative disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24371773" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Large granular lymphocytic leukemia associated with Lambert-Eaton Myasthenic Syndrome: A case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24138947" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Lambert-Eaton syndrome, an unrecognized treatable pediatric neuromuscular disorder: three patients and literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1314343" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Trends in the association of Lambert-Eaton myasthenic syndrome with carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24704152" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Surgery results in complete cure of Lambert-Eaton myasthenic syndrome in a patient with metastatic Merkel cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25702627" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Lambert-Eaton myasthenic syndrome associated with thymic neuroendocrine carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6247672" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Eaton-Lambert syndrome and malignant thymoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31586614" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Thymic Small Cell Carcinoma Associated With Lambert-Eaton Myasthenic Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18779614" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Screening for small-cell lung cancer: a follow-up study of patients with Lambert-Eaton myasthenic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20880069" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Screening for tumours in paraneoplastic syndromes: report of an EFNS task force.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21245427" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Clinical Dutch-English Lambert-Eaton Myasthenic syndrome (LEMS) tumor association prediction score accurately predicts small-cell lung cancer in the LEMS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19667272" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : SOX antibodies in small-cell lung cancer and Lambert-Eaton myasthenic syndrome: frequency and relation with survival.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31951874" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Neuronal antibody detection and improved lung cancer prediction in Lambert-Eaton myasthenic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6259555" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Treatment with oral 4-aminopyridine in disorders of neuromuscular transmission.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6259555" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Treatment with oral 4-aminopyridine in disorders of neuromuscular transmission.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6259555" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Treatment with oral 4-aminopyridine in disorders of neuromuscular transmission.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19357643" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert-Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10680790" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : A randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2555713" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : 3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19722254" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : 3,4-Diaminopyridine is more effective than placebo in a randomized, double-blind, cross-over drug study in LEMS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21328260" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Treatment for Lambert-Eaton myasthenic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26852139" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Amifampridine phosphate (Firdapse(®)) is effective and safe in a phase 3 clinical trial in LEMS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29280483" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : 3,4-diaminopyridine base effectively treats the weakness of Lambert-Eaton myasthenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29280483" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : 3,4-diaminopyridine base effectively treats the weakness of Lambert-Eaton myasthenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20979551" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : 3,4-diaminopyridine for the treatment of Lambert-Eaton myasthenic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11160470" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Long term outcome in Lambert-Eaton myasthenic syndrome without lung cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8797464" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9149073" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Long-term follow-up of Lambert-Eaton syndrome treated with intravenous immunoglobulin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9140371" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Treatment of Lambert-Eaton syndrome with intravenous immunoglobulin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8065398" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Effect of intravenous immunoglobulin in Lambert-Eaton myasthenic syndrome with small-cell lung cancer: correlation with the titer of anti-voltage-gated calcium channel antibody.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1620360" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Clinical and electrophysiologic improvement in Lambert-Eaton syndrome with intravenous immunoglobulin therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22454268" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Evidence-based guideline: intravenous immunoglobulin in the treatment of neuromuscular disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14530624" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Therapy with intravenous immunoglobulins: complications and side-effects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6272625" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Eaton-Lambert myasthenic syndrome: long-term treatment of three patients with prednisone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6114283" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Autoimmune aetiology for myasthenic (Eaton-Lambert) syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7114807" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Plasmapheresis and immunosuppressive drug therapy in the Eaton-Lambert syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6322050" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Plasma exchange and immunosuppressive drug treatment in the Lambert-Eaton myasthenic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12894384" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Therapy in myasthenia gravis and Lambert-Eaton myasthenic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14592920" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Lambert-eaton myasthenic syndrome: diagnosis and treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20392977" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23759215" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : [Favourable outcome after treatment with rituximab in a case of seronegative non-paraneoplastic Lambert-Eaton myasthenic syndrome].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10975475" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Apheresis treatment in Lambert-Eaton myasthenic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10023900" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Favourable prognosis in Lambert-Eaton myasthenic syndrome and small-cell lung carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28251917" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Long-term survival in paraneoplastic Lambert-Eaton myasthenic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18567862" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Lambert-Eaton myasthenic syndrome: tumor versus nontumor forms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31831596" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Long-term follow-up, quality of life, and survival of patients with Lambert-Eaton myasthenic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6297263" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Remission by chemotherapy of the Eaton-Lambert myasthenic syndrome in a patient with small cell bronchogenic carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6260327" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Remission of the Lambert-Eaton syndrome and small cell anaplastic carcinoma of the lung induced by chemotherapy and radiotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2170866" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Response of the Lambert-Eaton myasthenic syndrome to treatment of associated small-cell lung carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2558313" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : SFEMG improvement with remission in the cancer-associated Lambert-Eaton myasthenic syndrome.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
